EU/WHO-GMP pharma CDMO in Gujarat making oncology APIs, oral solids, injectables & liquids for 60+ markets
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 15 | 16 | 17 | 19 | 22 | 22 | 22 | 22 |
| Reserves | 66 | 83 | 110 | 154 | 241 | 264 | 281 | 302 |
| Borrowings | 17 | 43 | 93 | 119 | 79 | 86 | 72 | 55 |
| Other Liabilities | 17 | 37 | 47 | 44 | 47 | 43 | 73 | 101 |
| Total Liabilities | 115 | 178 | 268 | 336 | 389 | 415 | 449 | 481 |
| AssetsFixed Assets | 66 | 69 | 205 | 267 | 314 | 309 | 325 | 326 |
| CWIP | 13 | 49 | 1 | 6 | 0 | 17 | 17 | 4 |
| Investments | 0 | 0 | 7 | 3 | 0 | 0 | 0 | 0 |
| Other Assets | 36 | 60 | 55 | 60 | 74 | 90 | 107 | 151 |
| Total Assets | 115 | 178 | 268 | 336 | 389 | 415 | 449 | 481 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 16 | 19 | 15 | 36 | 33 | 24 | 34 | 49 |
| Cash from Investing | -25 | -22 | -47 | -90 | -74 | -52 | -31 | -28 |
| Cash from Financing | 9 | 3 | 32 | 55 | 41 | 27 | -3 | -21 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -9 | -4 | -32 | -62 | -49 | -35 | 2 | 21 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (47.6×) and current (51.6×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 45.7% growth and a 48× exit, ₹804 only delivers your return if you pay ₹2,461. The price is currently baking in 19% growth.
EPS grows 45.7%/yr for 5 years, then fades to 6% over 2, exits at 48×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 45.7% | 22.69 |
| FY28 | 45.7% | 33.05 |
| FY29 | 45.7% | 48.16 |
| FY30 | 45.7% | 70.17 |
| FY31 | 45.7% | 102.23 |
| FY32 | 25.9% ·fade | 128.66 |
| FY33 | 6.0% ·fade | 136.38 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.